IP Library › Granted Patent US 12,202,816

Granted Patent B2

US 12,202,816 · App. 17/278,489 · Granted Jan 21, 2025

Compounds as NADPH oxidase inhibitors

Inventors: Peter Machin (London, GB); Mark Chambers (Essex, GB); Alastair Hodges (Cambridgeshire, GB); Andrew Sharpe (Essex, GB); Grant Wishart (Essex, GB); Benjamin Perry (Collonges sous Saleve, FR); Sylvain Celanire (Reignier-Esery, FR); Freddy Heitz (Bernex, CH)

Assignee: CALLIDITAS THERAPEUTICS SUISSE SA

C07D401/14 A61P1/16 C07D405/14 C07D417/14 C07D491/107 C07D491/20 C07D498/04 A61K45/06

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 12,202,816
App. No.: 17/278,489
Granted: Jan 21, 2025
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Disclosed herein are new compounds, pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).

Claims (152)

1. A compound according to Formula (I):

wherein A 1 and A 2 groups are independently selected from hydrogen, halogen, CN, CF 3 , CHF 2 , an optionally substituted radical selected from C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, heteroalkyl, heterocycloalkyl, alkoxy, amino, carboxy, alkoxycarbonyl; A 3 is selected from hydrogen and halogen; R i is selected from the group of hydrogen, halogen, CN, CF 3 , CHF 2 , an optionally substituted radical selected from C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, heteroalkyl, heterocycloalkyl, carboxy; R ii is hydrogen or an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 3 -C 8 cycloalkyl, an optionally substituted halo C 1 -C 6 alkyl, an optionally substituted halo C 3 -C 8 cycloalkyl, an optionally substituted aryl C 1 -C 6 alkyl, an optionally substituted hereroaryl C 1 -C 6 alkyl, an optionally substituted heteroalkyl, an optionally substituted heterocycloalkyl, an optionally substituted heterocycloalkyl C 1 -C 6 alkyl, an optionally substituted hydroxy C 1 -C 6 alkyl, an optionally substituted alkoxy C 1 -C 6 alkyl, an optionally substituted alkoxycarbonyl C 1 -C 6 alkyl, an optionally substituted aminocarbonyl C 1 -C 6 alkyl, an optionally substituted aryl C 3 -C 8 cycloalkyl, an optionally substituted hereroaryl C 3 -C 8 cycloalkyl, an optionally substituted alkoxy C 3 -C 8 cycloalkyl, an optionally substituted amino C 3 -C 8 cycloalkyl, an optionally substituted halo C 3 -C 8 cycloalkyl; Ar 1 is selected from:

R 1 and R 4 are independently hydrogen, halogen, CN, CF 3 , CHF 2 , NH 2 , an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 3 -C 8 cycloalkyl, alkoxy, amino, an optionally substituted heterocycloalkyl, carboxy, an optionally substituted alkoxy C 1 -C 6 alkyl, an optionally substituted alkoxy C 3 -C 8 cycloalkyl, an optionally substituted amino C 1 -C 6 alkyl, an optionally substituted amino C 3 -C 8 cycloalkyl, an optionally substituted amino heterocycloalkyl C 1 -C 6 alkyl, an optionally substituted carboxy C 3 -C 8 cycloalkyl, an optionally substituted aminocarbonyl C 1 -C 6 alkyl; R 2 is selected from hydrogen, halogen, CF 3 , CHF 2 , NH 2 , an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 3 -C 8 cycloalkyl, an optionally substituted alkoxy, amino, an optionally substituted heterocycloalkyl, carboxy, an optionally substituted alkoxy C 1 -C 6 alkyl, an optionally substituted alkoxy C 3 -C 8 cycloalkyl, an optionally substituted amino C 1 -C 6 alkyl, an optionally substituted amino C 3 -C 8 cycloalkyl, an optionally substituted amino heterocycloalkyl C 1 -C 6 alkyl, an optionally substituted C 3 -C 8 carboxy cycloalkyl, an optionally substituted aminocarbonyl C 1 -C 6 alkyl; R 3 is selected from hydrogen, halogen, CF 3 , CHF 2 , NH 2 , an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 3 -C 8 cycloalkyl, an optionally substituted alkoxy, amino, an optionally substituted heterocycloalkyl, carboxy, an optionally substituted alkoxy C 1 -C 6 alkyl, an optionally substituted alkoxy C 3 -C 8 cycloalkyl, an optionally substituted amino C 1 -C 6 alkyl, an optionally substituted amino C 3 -C 8 cycloalkyl, an optionally substituted amino heterocycloalkyl C 1 -C 6 alkyl, an optionally substituted C 3 -C 8 carboxy cycloalkyl, an optionally substituted aminocarbonyl C 1 -C 6 alkyl; R 5 is selected from hydrogen, halogen, CF 3 , CHF 2 , NH 2 , an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 3 -C 8 cycloalkyl, an optionally substituted alkoxy, amino, an optionally substituted heterocycloalkyl, carboxy, an optionally substituted alkoxy C 1 -C 6 alkyl, an optionally substituted alkoxy C 3 -C 8 cycloalkyl, an optionally substituted amino C 1 -C 6 alkyl, an optionally substituted amino C 3 -C 8 cycloalkyl, an optionally substituted amino heterocycloalkyl C 1 -C 6 alkyl, an optionally substituted C 3 -C 8 carboxy cycloalkyl, an optionally substituted aminocarbonyl C 1 -C 6 alkyl; wherein when one from R 1 , R 2 , R 3 and R 4 is not H, the other from this group are H or any of R 1 , R 2 , R 3 , R 4 and R 5 can be linked together to form an optionally substituted bicyclic heteroaryl; Ar 1 is also selected from an optionally substituted bicyclic heteroaryl, in particular from the group consisting of:

wherein R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 and R 13 are each independently selected from hydrogen, halogen, hydroxy, CN, CF 3 , CHF 2 , NH 2 , alkoxy, amino, carboxy, aminocarbonyl, alkoxy carbonyl, or an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 3 -C 8 cycloalkyl, an optionally substituted halo alkyl, an optionally substituted heteroalkyl, an optionally substituted heterocycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted C 3 -C 8 cycloalkyl C 1 -C 6 alkyl, an optionally substituted heterocycloalkyl C 1 -C 6 alkyl, an optionally substituted aryl C 1 -C 6 alkyl, an optionally substituted heteroaryl C 1 -C 6 alkyl, an optionally substituted alkoxy C 1 -C 6 alkyl, an optionally substituted amino C 1 -C 6 alkyl, an optionally substituted carboxy C 1 -C 6 alkyl, an optionally substituted aminocarbonyl C 1 -C 6 alkyl, an optionally substituted heterocycloalkyl C 3 -C 8 cycloalkyl, an optionally substituted aryl C 3 -C 8 cycloalkyl, an optionally substituted heteroaryl C 3 -C 8 cycloalkyl, an optionally substituted alkoxy C 3 -C 8 cycloalkyl, an optionally substituted amino C 3 -C 8 cycloalkyl, an optionally substituted carboxy C 3 -C 8 cycloalkyl, an optionally substituted aminocarbonyl C 3 -C 8 cycloalkyl, acylamino, ureido, sulfonyl, sulfonylamino; Ar 2 is selected from the following group:

or from the following group:

wherein R 15 , R 16 and R 19 are independently selected from hydrogen, halogen, hydroxy, CN, CF 3 , CHF 2 , NH 2 , alkoxy, amino, carboxy, aminocarbonyl, alkoxy carbonyl, an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 3 -C 8 cycloalkyl, an optionally substituted alkenyl, alkynyl, an optionally substituted haloalkyl, an optionally substituted heteroalkyl, an optionally substituted heterocycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted C 3 -C 8 cycloalkyl C 1 -C 6 alkyl, an optionally substituted heterocycloalkyl C 1 -C 6 alkyl, an optionally substituted aryl C 1 -C 6 alkyl, an optionally substituted heteroaryl C 1 -C 6 alkyl, an optionally substituted alkoxy C 1 -C 6 alkyl, an optionally substituted amino C 1 -C 6 alkyl, an optionally substituted carboxy C 1 -C 6 alkyl, aminocarbonyl C 1 -C 6 alkyl, an optionally substituted heterocycloalkyl C 3 -C 8 cycloalkyl, an optionally substituted aryl C 3 -C 8 cycloalkyl, an optionally substituted heteroaryl C 3 -C 8 cycloalkyl, an optionally substituted alkoxy C 3 -C 8 cycloalkyl, an optionally substituted amino C 3 -C 8 cycloalkyl, an optionally substituted carboxy C 3 -C 8 cycloalkyl, an optionally substituted aminocarbonyl C 3 -C 8 cycloalkyl, acylamino, ureido and sulfonyl, or selected from the groups listed below:

Wherein y, w, z and t are independently an integer ranging from 1 to 3; h is an integer ranging from 0 to 3; n is an integer ranging from 0 to 4; G is selected from N—R 23 , O, S and SO 2 ; J is selected from C(B)n and N—R 23 ; L is C—(B) n, N—R 23 , O, S, SO 2 ; R 23 is selected from hydrogen, aminocarbonyl, alkoxy carbonyl, an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 3 -C 8 cycloalkyl, an optionally substituted halo alkyl, an optionally substituted heteroalkyl, an optionally substituted heterocycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, C 3 -C 8 cycloalkyl C 1 -C 6 alkyl, an optionally substituted heterocycloalkyl C 1 -C 6 alkyl, an optionally substituted aryl C 1 -C 6 alkyl, an optionally substituted heteroaryl C 1 -C 6 alkyl, alkoxy C 1 -C 6 alkyl, an optionally substituted amino C 1 -C 6 alkyl, an optionally substituted carboxy C 1 -C 6 alkyl, an optionally substituted aminocarbonyl C 1 -C 6 alkyl, an optionally substituted heterocycloalkyl C 3 -C 8 cycloalkyl, an optionally substituted aryl C 3 -C 8 cycloalkyl, an optionally substituted heteroaryl C 3 -C 8 cycloalkyl, an optionally substituted alkoxy C 3 -C 8 cycloalkyl, an optionally substituted amino C 3 -C 8 cycloalkyl, an optionally substituted carboxy C 3 -C 8 cycloalkyl, an optionally substituted aminocarbonyl C 3 -C 8 cycloalkyl and aminosulfonyl; B is selected from hydrogen, halogen, hydroxy, CN, CF 3 , CHF 2 , NH 2 , alkoxy, amino, carboxy, aminocarbonyl, alkoxy carbonyl, an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 3 -C 8 cycloalkyl, an optionally substituted halo alkyl, an optionally substituted heteroalkyl, an optionally substituted heterocycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted C 3 -C 8 cycloalkyl C 1 -C 6 alkyl, an optionally substituted heterocycloalkyl C 1 -C 6 alkyl, an optionally substituted aryl C 1 -C 6 alkyl, an optionally substituted heteroaryl C 1 -C 6 alkyl, an optionally substituted alkoxy C 1 -C 6 alkyl, an optionally substituted amino C 1 -C 6 alkyl, an optionally substituted carboxy C 1 -C 6 alkyl, aminocarbonyl C 1 -C 6 alkyl, an optionally substituted heterocycloalkyl C 3 -C 8 cycloalkyl, an optionally substituted aryl C 3 -C 8 cycloalkyl, an optionally substituted heteroaryl C 3 -C 8 cycloalkyl, an optionally substituted alkoxy C 3 -C 8 cycloalkyl, an optionally substituted amino C 3 -C 8 cycloalkyl, an optionally substituted carboxy C 3 -C 8 cycloalkyl, an optionally substituted aminocarbonyl C 3 -C 8 cycloalkyl, acylamino, ureido, sulfonyl and sulfonylamino; R 17 and R 18 are independently selected from hydrogen, halogen, CN, CF 3 , CHF 2 , alkoxy, amino, an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 3 -C 8 cycloalkyl, an optionally substituted halo alkyl, an optionally substituted heteroalkyl, an optionally substituted heterocycloalkyl, an optionally substituted C 3 -C 8 cycloalkyl C 1 -C 6 alkyl, an optionally substituted heterocycloalkyl C 1 -C 6 alkyl, an optionally substituted alkoxy C 1 -C 6 alkyl, an optionally substituted amino C 1 -C 6 alkyl, an optionally substituted heterocycloalkyl C 3 -C 8 cycloalkyl, an optionally substituted alkoxy C 3 -C 8 cycloalkyl, an optionally substituted amino C 3 -C 8 cycloalkyl, acylamino, ureido, sulfonyl, aminosulfonyl and sulfonylamino; R 20 and R 22 are independently selected from hydrogen, halogen, CN, CF 3 , CHF 2 , alkoxy, amino, an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 3 -C 8 cycloalkyl, an optionally substituted haloalkyl, an optionally substituted heteroalkyl, an optionally substituted heterocycloalkyl, an optionally substituted C 3 -C 8 cycloalkyl C 1 -C 6 alkyl, an optionally substituted heterocycloalkyl C 1 -C 6 alkyl, an optionally substituted alkoxy C 1 -C 6 alkyl, an optionally substituted amino C 1 -C 6 alkyl, an optionally substituted heterocycloalkyl C 3 -C 8 cycloalkyl, an optionally substituted alkoxy C 3 -C 8 cycloalkyl and an optionally substituted amino C 3 -C 8 cycloalkyl; R 21 is selected from hydrogen, aminocarbonyl, alkoxy carbonyl, an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 3 -C 8 cycloalkyl, an optionally substituted halo alkyl, an optionally substituted heteroalkyl, heterocycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted C 3 -C 8 cycloalkyl C 1 -C 6 alkyl, an optionally substituted heterocycloalkyl C 1 -C 6 alkyl, aryl C 1 -C 6 alkyl, an optionally substituted heteroaryl C 1 -C 6 alkyl, an optionally substituted alkoxy C 1 -C 6 alkyl, an optionally substituted amino C 1 -C 6 alkyl, an optionally substituted carboxy C 1 -C 6 alkyl, an optionally substituted aminocarbonyl C 1 -C 6 alkyl, an optionally substituted heterocycloalkyl C 3 -C 8 cycloalkyl, an optionally substituted aryl C 3 -C 8 cycloalkyl, an optionally substituted heteroaryl C 3 -C 8 cycloalkyl, an optionally substituted alkoxy C 3 -C 8 cycloalkyl, an optionally substituted amino C 3 -C 8 cycloalkyl, an optionally substituted carboxy C 3 -C 8 cycloalkyl and an optionally substituted aminocarbonyl C 3 -C 8 cycloalkyl; R 15 and R 16 can be linked together to form an optionally substituted bicyclic heteroaryl of formula

wherein X, Y and Z and each independently C(R 24 R 25 ), CH 2 C(R 24 R 25 ), C(═O), O and N—R 26 ; or

R 15 and R 16 can be linked together to form an optionally substituted bicyclic heteroaryl of formula

to form 3,4-dihydro-2H-pyrido [3,2-b][1,4]oxazine, wherein the nitrogen in the Z position is N—R 26 ; R 24 and R 25 are each independently selected from hydrogen, halogen, hydroxy, CN, CF 3 , CHF 2 , NH 2 , alkoxy, amino, carboxy, aminocarbonyl, alkoxy carbonyl, an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 3 -C 8 cycloalkyl, an optionally substituted halo alkyl, an optionally substituted heteroalkyl, an optionally substituted heterocycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted C 3 -C 8 cycloalkyl C 1 -C 6 alkyl, an optionally substituted heterocycloalkyl C 1 -C 6 alkyl, an optionally substituted aryl C 1 -C 6 alkyl, an optionally substituted heteroaryl C 1 -C 6 alkyl, an optionally substituted alkoxy C 1 -C 6 alkyl, an optionally substituted amino C 1 -C 6 alkyl, an optionally substituted carboxy C 1 -C 6 alkyl, an optionally substituted aminocarbonyl C 1 -C 6 alkyl, an optionally substituted heterocycloalkyl C 3 -C 8 cycloalkyl, an optionally substituted aryl C 3 -C 8 cycloalkyl, an optionally substituted heteroaryl C 3 -C 8 cycloalkyl, an optionally substituted alkoxy C 3 -C 8 cycloalkyl, an optionally substituted amino C 3 -C 8 cycloalkyl, an optionally substituted carboxy C 3 -C 8 cycloalkyl, an optionally substituted aminocarbonyl C 3 -C 8 cycloalkyl, acylamino, ureido, sulfonyl and sulfonylamino; R 24 and R 25 can be linked together to form an optionally substituted C 3 -C 8 cycloalkyl or an optionally substituted heterocycloalkyl; R 26 is selected from hydrogen, aminocarbonyl, alkoxy carbonyl, an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 3 -C 8 cycloalkyl, an optionally substituted halo alkyl, an optionally substituted heteroalkyl, an optionally substituted heterocycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted C 3 -C 8 cycloalkyl C 1 -C 6 alkyl, an optionally substituted heterocycloalkyl C 1 -C 6 alkyl, an optionally substituted aryl C 1 -C 6 alkyl, an optionally substituted heteroaryl C 1 -C 6 alkyl, an optionally substituted alkoxy C 1 -C 6 alkyl, amino C 1 -C 6 alkyl, an optionally substituted carboxy C 1 -C 6 alkyl, an optionally substituted aminocarbonyl C 1 -C 6 alkyl, an optionally substituted heterocycloalkyl C 3 -C 8 cycloalkyl, an optionally substituted aryl C 3 -C 8 cycloalkyl, an optionally substituted heteroaryl C 3 -C 8 cycloalkyl, an optionally substituted alkoxy C 3 -C 8 cycloalkyl, an optionally substituted amino C 3 -C 8 cycloalkyl, an optionally substituted carboxy C 3 -C 8 cycloalkyl and an optionally substituted aminocarbonyl C 3 -C 8 cycloalkyl, aminosulfonyl; R 15 and R 19 can be linked together to form an optionally substituted bicyclic heteroaryl; R 15 and R 21 can be linked together to form an optionally substituted bicyclic heteroaryl; R 17 and R 21 can be linked together to form an optionally substituted bicyclic heteroaryl; R 20 and R 21 can be linked together to form an optionally substituted bicyclic heteroaryl, wherein when A 3 is hydrogen at least one of A 1 and A 2 is not hydrogen, as well as a tautomer, a geometrical isomer, an optically active form, and a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein said compound is not 2,5-di(pyridin-4-yl)-1H-indole-3-carbonitrile or 5-(pyridin-3-yl)-2-(pyridin-4-yl)-1H-indole-3-carbonitrile or 2,5-di(pyridin-3-yl)-1H-indole-3-carbonitrile.

3. The compound according to claim 2 , wherein R i is H.

4. The compound according to claim 2 , wherein R i is halogen, in particular chloro.

5. The compound according to claim 2 , wherein R ii is H.

6. The compound according to claim 2 , wherein R ii is optionally substituted C 1 -C 6 alkyl such as optionally substituted methyl, optionally substituted ethyl, optionally substituted isopropyl, C 1 -C 6 alkyl optionally substituted with alkoxy such as methoxy ethyl or with optionally substituted C 2 -C 8 heterocycloalkyl such as oxetan methyl or with optionally substituted C 3 -C 8 cycloalkyl or with optionally substituted aryl C 1 -C 6 alkyl, or with an optionally substituted amide C 1 -C 6 alkyl or with optionally substituted acyl.

7. The compound according to claim 2 , wherein R ii is optionally substituted C 3 -C 8 cycloalkyl, such as an optionally substituted cyclopropyl.

8. The compound according to claim 2 , wherein A 1 and A 2 -groups are independently selected from hydrogen, halogen and optionally substituted C 1 -C 6 alkyl.

9. The compound according to claim 2 , wherein the compound is selected from the group consisting of:

1-(5-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl) pyridin-2-yl)-6-oxa-1-azaspiro [3.3]heptane;

1-(4-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl) pyridin-2-yl)-6-oxa-1-azaspiro [3.3]heptane;

1-(4-(6-chloro-5-(2-methylpyridin-4-yl)-1H-indol-2-yl) pyridin-2-yl)-6-oxa-1-azaspiro [3.3]heptane;

6-(5-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl) pyridin-2-yl)-2-oxa-6-azaspiro [3.3]heptane;

2-(5-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl) pyridin-2-yl)-7-oxa-2-azaspiro [3.5]nonane;

1-(5-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl) pyridin-2-yl)-3-methylazetidin-3-ol;

6-chloro-2-(6-(3,3-difluoroazetidin-1-yl) pyridin-3-yl)-5-(5-methoxypyridin-3-yl)-1H-indole

1-(5-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl) pyridin-2-yl) azetidine-3-carboxylic acid;

1-(5-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl) pyridin-2-yl) azetidine-3-carboxamide;

(1-(5-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl) pyridin-2-yl) azetidin-3-yl) methanol;

6-chloro-5-(5-methoxypyridin-3-yl)-2-(6-(3-methoxypyrrolidin-1-yl) pyridin-3-yl)-1H-indole;

N-(1-(5-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl) pyridin-2-yl) pyrrolidin-3-yl) methanesulfonamide;

(1-(5-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl) pyridin-2-yl) pyrrolidin-2-yl) methanol;

1-(5-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl) pyridin-2-yl)-5-(hydroxymethyl) pyrrolidin-2-one;

4-(5-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)-3-fluoropyridin-2-yl) morpholine;

6-chloro-5-(5-methoxypyridin-3-yl)-2-(6-(4-(oxetan-3-yl) piperazin-1-yl) pyridin-3-yl)-1H-indole;

6-chloro-2-(6-(4-ethylpiperazin-1-yl) pyridin-3-yl)-5-(5-methoxypyridin-3-yl)-1H-indole;

4-(5-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl) pyridin-2-yl)thiomorpholine 1,1-dioxide;

6-chloro-2-(6-(4,4-difluoropiperidin-1-yl) pyridin-3-yl)-5-(5-methoxypyridin-3-yl)-1H-indole;

4-(5-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl) pyridin-2-yl)-1-methylpiperazin-2-one;

3′-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)-1-methyl-5′H-spiro[azetidine-3,7′-furo[3,4-b]pyridine];

7-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)-4-methyl-3,4-dihydro-2H-pyrido [3,2-b][1,4]oxazine;

(5-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl) pyridin-2-yl) (oxetan-3-yl) methanol;

6-chloro-2-(6-(methoxy (oxetan-3-yl)methyl) pyridin-3-yl)-5-(5-methoxypyridin-3-yl)-1H-indole;

2-(5-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl) pyridin-2-yl) propan-1-ol;

5-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)-1-methylpyridin-2 (1H)-one;

4-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)-1-(cyclopropylmethyl) pyridin-2 (1H)-one;

4-(5-(7-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl) pyridin-2-yl) morpholine;

4-(5-(4,6-difluoro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl) pyridin-2-yl) morpholine;

4-(5-(6-chloro-5-(quinolin-5-yl)-1H-indol-2-yl) pyridin-2-yl) morpholine;

4-(5-(6-chloro-5-(5-chloropyridin-3-yl)-1H-indol-2-yl) pyridin-2-yl) morpholine;

4-fluoro-5-(5-methoxypyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;

6-fluoro-5-(5-methoxypyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;

4-chloro-5-(5-methoxypyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;

6-chloro-5-(5-methoxypyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;

5-(5-methoxypyridin-3-yl)-4-methyl-2-(2-methylpyridin-4-yl)-1H-indole;

5-(5-methoxypyridin-3-yl)-6-methyl-2-(2-methylpyridin-4-yl)-1H-indole;

4-methyl-2,5-di(pyridin-4-yl)-1H-indole;

6-methyl-2,5-di(pyridin-4-yl)-1H-indole;

4-(5-(4-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl) pyridin-2-yl) morpholine;

4-(5-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl) pyridin-2-yl) morpholine;

4-chloro-2,5-di(pyridin-4-yl)-1H-indole

6-chloro-2,5-di(pyridin-4-yl)-1H-indole;

N,N dimethyl 4 (2 (2 methylpyridin 4 yl) 1H indol 5 yl)pyridin 2 amine;

5-(6-chloro-2-(6-morpholinopyridin-3-yl)-1H-indol-5-yl) quinolin-2-ol;

4-(5-(6-chloro-5-(thieno[2,3-c]pyridin-4-yl)-1H-indol-2-yl) pyridin-2-yl) morpholine;

4-(5-(6-chloro-5-(6-fluoroquinolin-4-yl)-1H-indol-2-yl) pyridin-2-yl) morpholine;

4-(5-(6-chloro-5-(2-methoxyquinolin-5-yl)-1H-indol-2-yl) pyridin-2-yl) morpholine;

4-(5-(6-chloro-5-(5-methoxypyridin-3-yl)-1-methyl-1H-indol-2-yl) pyridin-2-yl) morpholine;

7-(4-chloro-5-(5-methoxypyridin-3-yl)-1-methyl-1H-indol-2-yl)-4-methyl-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine; and

7-(6-chloro-5-(5-methoxypyridin-3-yl)-1-methyl-1H-indol-2-yl)-4-methyl-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine.

10. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier, diluent or excipient thereof.

11. A method for treating a disorder, a disease, or condition selected from a cardiovascular disorder, a respiratory disorder, a metabolic disorder, a skin disorder, a bone disorder, a neuroinflammatory and/or neurodegenerative disorder, a kidney disorder, a reproduction disorder, a disease affecting the eye and/or the lens and/or a condition affecting the inner ear, an inflammatory disorder, a liver disease, pain, a cancer, a fibrotic disorder, a psychotic disorder, an infectious disease, an allergic disorder, traumatism, septic, hemorrhagic and anaphylactic shock, a disease or a disorder of the gastrointestinal system, angiogenesis and angiogenesis-dependent and other disease and/or disorder associated with Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase) in a subject in need thereof, said method comprising administering to the subject a compound of claim 1 .

12. The method of claim 11 , wherein the disease or condition is selected from an inflammatory disorder, a fibrotic disorder, a pain condition, or an angiogenic disorder.

13. The method of claim 12 , wherein the disease or condition is an inflammatory disorder, and wherein the inflammatory disorder is selected from skin inflammation, liver inflammation, and central nervous system inflammation.

14. The method of claim 12 , wherein the disease or condition is a fibrotic disorder, wherein the fibrotic disorder is selected from pulmonary fibrosis, kidney fibrosis, liver fibrosis, corneal fibrosis, skin fibrosis, and in a cancer with a fibrotic stromal component.

15. The method of claim 11 , wherein the disease or condition is a cancer, wherein the cancer is selected from head and neck cancer, breast cancer, colorectal cancer, melanoma, lung cancer and glioblastoma.

16. The method of claim 11 , wherein the disease or condition is a pain disorder, wherein the pain disorder is selected from neuropathic pain in particular diabetic neuropathy, spinal or nerve injury related pain, amputation, drug induced pain, multiple sclerosis, multiple myeloma, shingles, Lyme disease, Herpes Zoster infection, cancer related pain, HIV-related pain, trigeminal neuralgia and inflammatory pain.

17. The method of claim 11 , wherein the disease or condition is an angiogenic disorder, wherein the angiogenic disorder is selected from a cancer with solid tumors or benign and malignant vascular tumors endometriosis and proliferative retinopathies.

18. The method of claim 11 , wherein said compound is to be administered to the subject in combination with a co-agent useful in the treatment of cancer.

19. The method of claim 11 , wherein said compound is to be administered to the subject in combination with an agent targeting cell-surface proteins.

20. The method of claim 11 , wherein said compound is to be administered to the subject in combination with radiation therapy.

21. A compound selected from the group consisting of:

5-(2-methoxypyridin-4-yl)-2-(2-methylpyridin-4-yl)-1H-indole;

2,5-bis(2-methylpyridin-4-yl)-1H-indole;

4-(2-(2-methylpyridin-4-yl)-1H-indol-5-yl) pyridin-2-amine;

5-(5-fluoropyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;

5-(5-chloropyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;

5-(5-isopropoxypyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;

N,N-dimethyl-5-(2-(2-methylpyridin-4-yl)-1H-indol-5-yl) pyridin-3-amine;

5-(6-methylpyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;

2-(2-methylpyridin-4-yl)-5-(pyrimidin-5-yl)-1H-indole;

2-methyl-5-(2-(2-methylpyridin-4-yl)-1H-indol-5-yl)-1H-benzo[d]imidazole;

2-(2-(azetidin-1-yl) pyridin-4-yl)-5-(5-methoxypyridin-3-yl)-1H-indole;

5-(5-methoxypyridin-3-yl)-2-(2-methoxypyridin-4-yl)-1H-indole;

2-(2,6-dimethylpyridin-4-yl)-5-(5-methoxypyridin-3-yl)-1H-indole;

5-(5-methoxypyridin-3-yl)-2-(2-methylpyrimidin-4-yl)-1H-indole;

5-(5-methoxypyridin-3-yl)-2-(1-methyl-1H-imidazol-5-yl)-1H-indole;

4-(5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)-2-methylthiazole;

2-(2-cyclopropylpyridin-4-yl)-5-(5-methoxypyridin-3-yl)-1H-indole;

1-(4-(5-(5-methoxypyridin-3-yl)-1H-indol-2-yl) pyridin-2-yl) azetidin-3-ol;

1-(4-(5-(5-methoxypyridin-3-yl)-1H-indol-2-yl) pyridin-2-yl)-6-oxa-1-azaspiro[3.3] heptane;

2-(2-(4,4-difluoropiperidin-1-yl) pyridin-4-yl)-5-(5-methoxypyridin-3-yl)-1H-indole;

4-(4-(5-(5-methoxypyridin-3-yl)-1H-indol-2-yl) pyridin-2-yl) morpholine;

2-(5-fluoropyridin-3-yl)-5-(5-methoxypyridin-3-yl)-1H-indole;

5-(5-methoxypyridin-3-yl)-2-(6-methoxypyridin-3-yl)-1H-indole;

4-(5-(5-(5-methoxypyridin-3-yl)-1H-indol-2-yl) pyridin-2-yl) morpholine;

5-(5-methoxypyridin-3-yl)-2-(6-(oxetan-3-yl) pyridin-3-yl)-1H-indole;

1-(5-(5-(5-methoxypyridin-3-yl)-1H-indol-2-yl) pyridin-2-yl)-6-oxa-1-azaspiro[3.3] heptane;

N,N-dimethyl-5-(5-(2-methylpyridin-4-yl)-1H-indol-2-yl) pyridin-2-amine;

4-(5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)-N,N-dimethylpyridin-2-amine;

N,N-dimethyl-4-(5-(quinolin-4-yl)-1H-indol-2-yl) pyridin-2-amine;

N,N-dimethyl-4-(2-(2-methylpyridin-4-yl)-1H-indol-5-yl) pyridin-2-amine;

5-(6-cyclopropylpyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;

5-(6-methoxypyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;

5-(6-(methoxymethyl) pyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;

5-(5-ethoxypyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;

5-(5-cyclopropoxypyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;

5-(5-(cyclopropylmethoxy)pyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;

5-(5-cyclopropylpyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;

7-(2-(2-methylpyridin-4-yl)-1H-indol-5-yl)-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine;

3-(2-(2-methylpyridin-4-yl)-1H-indol-5-yl) quinoline;

N-methyl-4-(2-(2-methylpyridin-4-yl)-1H-indol-5-yl) pyridin-2-amine;

4-(4-(2-(2-methylpyridin-4-yl)-1H-indol-5-yl) pyridin-2-yl) morpholine;

4-(5-(6-fluoroquinolin-4-yl)-1H-indol-2-yl)-N,N-dimethylpyridin-2-amine;

4-(5-(isoquinolin-4-yl)-1H-indol-2-yl)-N,N-dimethylpyridin-2-amine;

N,N-dimethyl-4-(5-(quinolin-5-yl)-1H-indol-2-yl) pyridin-2-amine;

3-chloro-2,5-di(pyridin-4-yl)-1H-indole;

2-(2-methylpyridin-4-yl)-5-(pyridin-4-yl)-1H-indole;

5-(5-methoxypyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;

5-(5-methoxypyridin-3-yl)-2-(pyridin-4-yl)-1H-indole;

5-(5-methoxypyridin-3-yl)-2-(pyridin-3-yl)-1H-indole;

4-(2-(pyridin-4-yl)-1H-indol-5-yl) quinoline;

4-(2-(pyridin-3-yl)-1H-indol-5-yl) quinoline;

2,5-di(pyridin-4-yl)-1H-indole;

2-(pyridin-3-yl)-5-(pyridin-4-yl)-1H-indole;

2,5-di(pyridin-3-yl)-1H-indole;

2-(1-methyl-1H-pyrazol-5-yl)-5-(pyridin-4-yl)-1H-indole;

5-(2-(4-methylpiperazin-1-yl) pyridin-4-yl)-2-(pyridin-4-yl)-1H-indole;

5-(5-methoxypyridin-3-yl)-2-(pyridin-2-yl)-1H-indole;

5-(5-methoxypyridin-3-yl)-2-(pyrimidin-4-yl)-1H-indole;

2-(3-fluoropyridin-4-yl)-5-(5-methoxypyridin-3-yl)-1H-indole;

1-isopropyl-5-(5-methoxypyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;

1-(2-methoxyethyl)-2,5-di(pyridin-4-yl)-1H-indole;

1-(2-methoxyethyl)-5-(5-methoxypyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;

1-methyl-5-(5-methoxypyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;

1-ethyl-5-(5-methoxypyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;

1-(cyclopropylmethyl)-5-(5-methoxypyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;

1-(benzyl)-5-(5-methoxypyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;

1-cyclopropyl-5-(5-methoxypyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;

1-methyl-2,5-di(pyridin-4-yl)-1H-indole; and

5-(5-methoxypyridin-3-yl)-2-(3-methylpyridin-4-yl)-1H-indole;

or a pharmaceutically acceptable salt thereof.

Assignments (2)

CHANGE OF NAME Recorded Jul 9, 2024

From: GENKYOTEX SUISSE SA

To: CALLIDITAS THERAPEUTICS SUISSE SA

Reel/Frame 067935/0912 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 27, 2021

From: MACHIN, PETER; CHAMBERS, MARK; HODGES, ALASTAIR; SHARPE, ANDREW; WISHART, GRANT; PERRY, BENJAMIN; CELANIRE, SYLVAIN; HEITZ, FREDDY

To: GENKYOTEX SUISSE SA

Reel/Frame 057930/0097 →

Priority Claims (1)

EP 18197787 · Sep 28, 2018 · regional

Continuity (1)

Related Publication 20220033379A1 · Feb 3, 2022

References Cited (51)

US 20070105866A1 · Hutchinson et al. · 2007 [cited by applicant]

WO WO200114371 · 2001 [cited by applicant]

WO WO2008116926 · 2008 [cited by applicant]

WO WO2008116926A1 · 2008 [cited by examiner]

WO WO2010045188 · 2010 [cited by applicant]

WO US20110071150A1 · 2011 [cited by examiner]

WO WO2011036130 · 2011 [cited by applicant]

WO WO2011151619 · 2011 [cited by applicant]

WO WO2012173952 · 2012 [cited by applicant]

WO WO2013010904 · 2013 [cited by applicant]

WO WO2013064468 · 2013 [cited by applicant]

WO WO2014106649 · 2014 [cited by applicant]

WO WO2014153227 · 2014 [cited by applicant]

WO WO2015138273 · 2015 [cited by applicant]

WO WO2019086579 · 2019 [cited by applicant]

WO WO2019126253 · 2019 [cited by applicant]

Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. Jul. 6, 2012;18(7):1028-40 (Year: 2012). [cited by examiner]

Duan et al., J Am Chem Soc., 2016, vol. 138, No. 51, pp. 16686-16695. [cited by applicant]

He et al., ACS Nano, 2015, vol. 9, p. 991. [cited by applicant]

Thabut et al., 2002, J. Biol. Chem., 277:22814-22821. [cited by applicant]

Brigham, 1986, Chest, 89(6): 859-863. [cited by applicant]

Djordjevic et al., 2005, Arterioscler. Thromb. Vasc. Biol., 25, 519-525. [cited by applicant]

Liu et al., 2004, Am. J. Physiol. Lung, Cell. Mol. Physiol., 287:L111-118. [cited by applicant]

Yang et al., 2002, J. Cell. Chem. 84, 645-654. [cited by applicant]

Ellis et al., 2000, Free Rad. Biol. Med., 28:91-101. [cited by applicant]

Pillarisetti et al., 2004, Expert Opin. Ther. Targets, 8(5):401-408. [cited by applicant]

Cai et al., 2003, Trends Pharmacol. Sci., 24:471-478. [cited by applicant]

Shi et al., 2001, Throm. Vasc. Biol., 2001, 21, 739-745. [cited by applicant]

Nunomura et al., 2001, J. Neuropathol. Exp. Neurol., 60:759-767. [cited by applicant]

Girouard, 2006, J. Appl. Physiol. 100:328-335. [cited by applicant]

Vernet et al., Biol. Reprod., 2001, 65:1102-1113. [cited by applicant]

Lambeth et al. 2008, Semin. Immunopathol., 2008, 30, 339-363. [cited by applicant]

Garrido-Urbani, 2011, PLoS ONE, 6(2). [cited by applicant]

Leto et al., 2006, Antioxid. Redox Signal, 8(9-10):1549-61. [cited by applicant]

Cheng et al., 2001, Gene, 16; 269(1-2):131-40. [cited by applicant]

Rynayhossani et al., 2013, J. Bio. Chem., 288(51):36437-50. [cited by applicant]

Gianni et al., 2010, ACS Chem. Biol., 5(10):981:93. [cited by applicant]

Wilkinson-Berka et al., 2014, Antioxid. Redox Signal, 20(17):2726-40. [cited by applicant]

Carnesecchi et al., 2009, American Journal of Respiratory and Critical Care Medicine; 180(10):972-981. [cited by applicant]

Philip J. Kocienski, in “Protecting Groups”, Georg Thieme Verlag Stuttgart, 2005. [cited by applicant]

Theodora W. Greene and Peter G. M. Wuts in “Protective Groups in Organic Synthesis”, Wiley Interscience, 4th Edition 2006. [cited by applicant]

Palicz et al., 2001, J. Biol. Chem, 76, 3090. [cited by applicant]

Bartlett et al., 2013, Molecular Cancer 2, 12:10 PCT Spec. [cited by applicant]

Fukuhara et al., 2016, Cancer Sci, 107(10), 1373-1379. [cited by applicant]

Perica et al., 2015, Rambam Maimonides Med J 6(1), e0004. [cited by applicant]

Iwai et al., 2017, Journal of Biomedical Science, 24:26. [cited by applicant]

Mishra, 2017, Future Oncol. doi: 10.2217/fon-2017-0115. [cited by applicant]

Soto Chervin et al., 2016, F1000Research 2016, 5(F1000 Faculty Rev):803. [cited by applicant]

Mertens et al., “Nonsteroidal Cardiotonics. 3. New 4,5-Dihydro-6-(1H-Indol-5-YL)Pyridazin-3(2H)-Ones and related compounds with positive inotropic activities” J of Med Chem, Am Chem Soc, vol. 33, No. 10, Jan. 1, 1990. [cited by applicant]

International Search Report and Written Opinion were mailed on Jan. 2, 2020 by the International Searching Authority for International Application No. PCT/EP2019/076273, filed on Sep. 27, 2019 and published as WO 2020/0… [cited by applicant]

Bobko, Mark, et al. “Synthesis of 2, 5-disubstituted-3-cyanoindoles” Tetrahedron Letters, Elsevier, Amsterdam, The Netherlands, vol. 53, No. 2, Nov. 3, 2011, pp. 200-202. [cited by applicant]